Current Report Filing (8-k)
October 19 2020 - 9:16AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 16, 2020
CANCER
GENETICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-35817
|
|
04-3462475
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
201
Route 17 North 2nd Floor
Rutherford,
New Jersey 07070
(Address
of principal executive offices)
Registrant’s
telephone number, including area code: (201) 528-9200
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
CGIX
|
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
On October 16, 2020, Cancer Genetics, Inc.
(the “Company”) and Glenn Miles, the Company’s Chief Financial Officer, mutually determined that Mr. Miles would
cease his employment as Chief Financial Officer, effective November 16, 2020 (the “Separation Date”). Mr. Miles will
receive his current compensation through the Separation Date and additional compensation comprised of a one-time payment equal
to $5,000 for execution of a separation agreement and mutual release of claims and, conditioned on his completion of certain
critical tasks associated with the transition process leading up to the Separation Date, payment of up to an additional $35,000.
In addition, Mr. Miles will be provided with an extension, through one year after the Separation Date, of the exercise period
for his vested stock options. His departure as an officer of the Company is not due to a dispute or disagreement with the Company.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CANCER
GENETICS, INC.
|
|
|
|
Dated:
October 19, 2020
|
By:
|
/s/
John A. Roberts
|
|
Name:
|
John
A. Roberts
|
|
Title:
|
Chief
Executive Officer
|
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Sep 2023 to Sep 2024